Navigation Links
Global Cervical Cancer Vaccine Market to Cross US$ 1.6 billion by 2020 Says Pharmaion
Date:12/3/2015

BURNABY, Canada, December 3, 2015 /PRNewswire/ --

Growing prevalence of cervical cancer coupled with favorable government initiatives to drive global cervical cancer vaccine market through 2020 

According to recently published Pharmaion report, "Global Cervical Cancer Vaccine Market Opportunities, 2020", global cervical cancer vaccine market is anticipated to cross US$ 1.6 billion by 2020. Growth in the market is anticipated on account of rising prevalence of cervical cancer, various promising late-stage pipeline candidates and vendors' patient-assistance programs. Moreover, governments in various countries are also organizing different programs and initiatives to increase awareness regarding cervical cancer and associated vaccines available in the market. Furthermore, reduction in the number of recommended number of doses of HPV immunisation from three to two is also expected to have a positive impact on the global cervical cancer vaccine market during 2015 - 2020.

Cervical cancer vaccines are biological preparations that stimulate or strengthen a person's immune system against cancer. Majorly, two cervical cancer vaccines, namely, Gardasil (Merck & Co., Inc.) and Cervarix (GlaxoSmithKline plc), are available across the globe. Gardasil and Cervarix provide protection against four and two types of HPV strains, respectively. As of 2014, Merck & Co., Inc. and GlaxoSmithKline plc were the only two HPV vaccine producers in the global cervical cancer market. However, Xiamen Innovax Biotech Co., Ltd. plans to enter the global cervical cancer market with the launch of its bivalent HPV vaccine Cecolin.

Region-wise, the United States dominated the global cervical cancer market and is anticipated to continue its dominance through 2020 on account of the launch of its nine-valent HPV vaccine, Gardasil 9, in 2014, which protects against the infection of all nine types of HPV. Moreover, growing prevalence of cervical cancer, high per capital income levels and favorable reimbursement policies are expected to result in continuance of US as the largest global cervical cancer vaccine market through 2020.

"Various strategic alliances are being signed between public and private entities for increasing the penetration of cervical cancer vaccine. For instance, GAVI Alliance aims to immunize about 2 million females in developing regions in 2015 using the HPV vaccines Cervarix and Gardasil, which are being supplied at a low cost by GlaxoSmithKline and Merck. Moreover, in the US, National Vaccine Program Office (NVPO) inked a partnership contract with the American Pharmacists Association (APhA) in 2015 in order to utilize alternative vaccination sites, such as pharmacies, to increase the vaccination access and coverage rates in the country." said Mr. Karan Chechi, Research Director with Pharmaion, a research based global pharmaceutical and healthcare consulting firm.

"Global Cervical Cancer Vaccine Market Opportunities, 2020" has analyzed the potential of the global cervical cancer vaccine market and provides statistics and information on market sizes, shares and trends. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyzes the emerging trends along with essential drivers and key challenges faced by the global cervical cancer vaccine market.

About Pharmaion 

Pharmaion is a research based management consulting firm focused exclusively on Healthcare & Pharmaceutical industry. Led by a team of dynamic industry experts, Pharmaion provides its customers with high value market research and advisory services that helps them identify new market opportunities, growth engines and innovative ways to capture the market share. As a result, Pharmaion's clients lead rather than follow market trends. Pharmaion has developed a proprietary database which focuses on identifying the unexplored opportunities in Healthcare and Pharmaceutical industry.

Media Contact
Karan Chechi
Research Director
Contact Phone- +1 646 360 1656
Email- sales@pharmaion.com



'/>"/>
SOURCE Pharmaion Consultants
Copyright©2015 PR Newswire.
All rights reserved


Related medicine technology :

1. Global Information Online Market Research Portal Provides Complimentary Sample Service for Customers to Preview Reports by Global Industry Analysts
2. Cumberland Pharmaceuticals To Present At The UBS Global Healthcare Conference In New York
3. The Rockley Group and Content Rules Ink Deal to Extend Global Reach
4. AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference
5. Amgen To Present At The UBS Global Life Sciences Conference
6. HeartWare Presentation At The 2013 UBS Global Healthcare Conference To Be Webcast
7. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City
8. PENTAX Medical And Hitachi-Aloka Medical Continue Joint Innovation And Global Leadership In Endoscopic Ultrasound Systems
9. Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
10. TRACE Releases 2012 Global Enforcement Report
11. Valeant Pharmaceuticals To Present At 34th Annual Goldman Sachs Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2018)... ... October 12, 2018 , ... ... open, welcoming applications from healthcare providers, students, trainees, and researchers worldwide. Winning proposals ... as microbiome sequencing and bioinformatics services. , “uBiome is thrilled to further expand ...
(Date:10/13/2018)... Fla. (PRWEB) , ... October 13, 2018 , ... In ... period taking on one massive brand after another. 2018 has been a game-changing year ... categories have all played a large role in the growth. Ion Labs attributes its ...
(Date:10/11/2018)... ... 11, 2018 , ... In the last four months it has also obtained ... allowance of six more in USA, China and Japan from three other patent families ... and security products. , The patents assigned from QinetiQ include US 7113092, titled “Ferromagnetic ...
Breaking Medicine Technology:
(Date:10/16/2018)... ... October 15, 2018 , ... LGC Maine Standards ... Number 205bf, for easier linearity and calibration verification. , The kit, in ... verification and verification of the reportable range for Albumin (ALB), Amylase (AMY), Cholesterol ...
(Date:10/16/2018)... (PRWEB) , ... October 16, ... ... a Texas-based healthcare and clinical research networking-technology company founded by patient-survivors, and ... quality and compliance in the clinical trial execution process, today announced its ...
(Date:10/13/2018)... ... 2018 , ... Convoy of Hope’s Disaster Services Team is currently in Marianna, ... set up to serve hurricane survivors with water, food, baby products, hygiene kits, flood ... additional truckloads of supplies are in motion to Florida. , Convoy’s walk-up ...
(Date:10/11/2018)... CHURCH, Va. (PRWEB) , ... October 11, 2018 ... ... and services, today announced the acquisition of J.Lodge, an industry leader in contact ... story —a lifelong survivor of a debilitating medical condition—J. Lodge supports alternative work ...
(Date:10/11/2018)... ... October 11, 2018 , ... ... and quite vulnerable to manipulation,” warns former U.S. Department of Homeland Security deputy ... We’re Vulnerable and How We Can Stop it. , Pointing to the ability ...
Breaking Medicine News(10 mins):